분자진단 시장 - 기회와 성장 지표

The molecular diagnostics industry is undergoing consolidation, requiring capital investment and faster regulatory pathways to accelerate clinical adoption. Major diagnostics and life sciences companies are acquiring proprietary testing platforms to strengthen positions in precision oncology and blood-based diagnostics. AI-enabled genomic workflow systems are emerging as key competitive differentiators by enabling large-scale genomic interpretation and improving accessibility of advanced diagnostics in routine care. The convergence of dPCR, NGS, CRISPR-Cas, and nanotechnology is creating multi-platform molecular testing ecosystems with improved speed, accuracy, and scalability across oncology, infectious diseases, and precision medicine. NGS continues to drive adoption through rapid, cost-effective multi-gene analysis for oncology, rare diseases, and reproductive health, with companies such as MGI Tech expanding access through automated sequencing solutions. The sector is also witnessing increased mergers and acquisitions aimed at portfolio expansion, R&D enhancement, and commercialization acceleration. Simultaneously, AI is evolving into a laboratory co-pilot, improving operational efficiency and diagnostic accuracy through integration with LIMS and human-in-the-loop clinical validation frameworks. Companion diagnostics are becoming central to precision medicine, with collaborations between Thermo Fisher and Pfizer, Guardant Health and Pfizer, and Illumina with pharmaceutical companies enabling targeted therapies supported by validated molecular testing.

Table of Contents

Research Scope

• Scope of Analysis
• Global Molecular Diagnostics Application Segmentation

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8TM
• The Impact of the Top 3 Strategic Imperatives on the Industrial Engineering Industry

Growth Opportunity Analysis

• Growth Metrics
• Growth Drivers
• Growth Driver Analysis
• Growth Restraints
• Growth Restraint Analysis
• Growth Drivers Accelerating Molecular Diagnostics Market Expansion
• Four Structural Shifts Redefining MDx
• The Molecular Diagnostics Technology Convergence Matrix
• Market Trend 1: Rising Demand for Rapid Diagnostics Accelerates Growth in the Molecular Diagnostics Industry
• Market Trend 2: NGS Adoption Expanding Market Leadership in Personalized Medicine
• Market Trend 3: M&A Momentum Reshaping Competitive Dynamics in the Molecular Diagnostics Industry
• Market Trend 4: Emerging Technologies Driving Competitive Differentiation in Molecular Diagnostics
• The Al Co-Pilot: Workflow Automation to Diagnostic Precision
• The Digital Backbone Powering Scalable Molecular Diagnostics
• Molecular Diagnostics and Pharma Interlock Through Companion Diagnostics
• The Companion Diagnostics (CDx) Flywheel
• Consolidating the Precision Molecular Oncology Care Continuum
• Global Molecular Diagnostics Competitive Landscape
• Competitive Landscape: Emerging Players
• Competitive Landscape of Molecular Diagnostics: Race Toward Early Detection and AI-Led Platforms
• Unlocking Value Through Diagnostics–Pharma Synergies
• Broader Infrastructure Moves Support the Core Molecular Trends
• The Regulatory Reality: A Harmonization Roadmap
• Changing Regulatory Dynamics in the Molecular Diagnostics Market

Growth Opportunity Universe

• Growth Opportunity 1: AI-Integrated Molecular Diagnostics Platforms Accelerate Precision Medicine and Clinical Decision Support
• Growth Opportunity 2: Multiomics Liquid Biopsy Platforms Expand Early Cancer Detection and Minimal Residual Disease Monitoring
• Growth Opportunity 3: Expansion of NGS Enabling Comprehensive Genomic Profiling
• Growth Opportunity 4: Pharmacogenomics-Driven Molecular Testing Enhances Personalized Drug Selection and Treatment Outcomes

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• List of Exhibits